Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18824777 | 0.99 | HRH3 (0.56) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL18844624 | 0.96 | HRH3 (0.52) | HRH3KCNH2ACHERAD52HRH1 | |
| SCHEMBL585479 | 0.93 | PSMB1 (0.55) | HRH3 | |
| SCHEMBL871366 | 0.92 | LTA4H (0.54) | HRH3 | |
| SCHEMBL22604522 | 0.90 | RAB9A (0.54) | HRH3KCNH2 | |
| SCHEMBL701173 | 0.88 | HRH3 (0.64) | HRH3KCNH2HRH1 | |
| SCHEMBL31584023 | 0.87 | HRH3 (0.53) | HRH3KCNH2HRH1MEN1KMT2A | |
| SCHEMBL8443537 | 0.84 | KDM4E (0.57) | HRH3MEN1KMT2A | |
| SCHEMBL1561408 | 0.83 | HRH2 (0.53) | HRH3KCNH2HRH1 | |
| SCHEMBL1367081 | 0.83 | LTA4H (0.52) | HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | disclosed |
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4442317-A2 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2024-10-09 | — | — | EP | disclosed |
| EP-3971177-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2024-06-26 | — | — | EP | disclosed |
| EP-3971177-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114014844-A | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-109641871-B | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3487851-B1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | NOVARTIS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | NOVARTIS AG (CH) | 2021-03-16 | — | — | US | disclosed |
| US-8076331-B2 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2303882-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2011-04-06 | — | — | EP | disclosed |
| US-20100311752-A1 | Substituted pyridazine derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2252593-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | Cephalon, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150381-A2 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009097306-A1 | SUBSTITUTED PYRIDAZINE DERIVATIVES WHICH HAVE HISTAMINE H3 ANTAGONIST ACTIVITY | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466808-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR1, ACVR1B | HRH3 1591/4885KCNH2 555/4885ACHE 4436/4885 |
| US-10947218-B2 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | ALK, ACVR2B, ACVR1B | HRH3 1501/4885KCNH2 531/4885ACHE 4396/4885 |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | HRH3 57/4885KCNH2 1043/4885ACHE 4362/4885 |
| US-20100311752-A1 | Substituted pyridazine derivatives | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 390/4885ACHE 327/4885 |
| US-20260116869-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | HRH3 452/4885KCNH2 350/4885ACHE 4758/4885 |
| US-20210155606-A1 | AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS | ALK, ACVR1, ACVR1B | HRH3 1591/4885KCNH2 555/4885ACHE 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.